Menu
← Oncology Approval Tracker
FDA DECISION ·
Piqray + fulvestrant
alpelisib with fulvestrant · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Expanded to premenopausal and perimenopausal women with HR-positive, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer after progression on endocrine therapy, as part of the adult indication with fulvestrant and FDA-approved mutation testing.
LAMPGEN ANALYSIS
Why it matters
The supplement broadened the labeled population and updated guidance for managing hyperglycemia.
What research teams should watch
Document menopausal status and any ovarian suppression plan, and set up baseline glucose and early follow-up.
PRIMARY RECORDS